Nationally Ranked Investors’ Rights Firm Holzer & Holzer, LLC Announces Investigation of Instil Bio, Inc. (TIL)

Rhea-AI Summary

Holzer & Holzer, LLC is investigating Instil Bio (NASDAQ:IL) for potential violations of federal securities laws. Following the company's announcement on October 31, 2022, regarding a pause in enrollment in clinical trials of ITIL-168 and ITIL-306 due to manufacturing issues, its stock price experienced a decline. The firm encourages investors who suffered losses to contact them for legal rights discussions.

Positive

• None.

Negative

• Stock price dropped following the announcement of a pause in clinical trials.
• Issues in manufacturing led to inability to dose patients.
• Concerns regarding compliance with federal securities laws.

ATLANTA, GA / ACCESSWIRE / November 7, 2022 / Holzer & Holzer, LLC is investigating whether Instil Bio, Inc. ("Instil Bio" or the "Company") (NASDAQ:IL) complied with federal securities laws. On October 31, 2022, Instil Bio announced a pause in enrollment in its ongoing clinical trials of ITIL-168 and ITIL-306 due to "a recent decrease in the rate of successful manufacturing of ITIL-168, resulting in the inability to dose some patients whose individual product of ITIL-168 was not successfully manufactured." Following this announcement, the Company's stock price dropped.

If you purchased Instil Bio stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at https://holzerlaw.com/case/instil-bio/ to discuss your legal rights.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

CONTACT: 

Corey Holzer, Esq. 
(888) 508-6832 (toll-free) 
cholzer@holzerlaw.com

SOURCE: Holzer & Holzer, LLC

View source version on accesswire.com:
https://www.accesswire.com/724409/Nationally-Ranked-Investors-Rights-Firm-Holzer-Holzer-LLC-Announces-Investigation-of-Instil-Bio-Inc-TIL

FAQ

What did Instil Bio announce on October 31, 2022?

Instil Bio announced a pause in enrollment in its clinical trials of ITIL-168 and ITIL-306 due to manufacturing issues.

How did the announcement affect Instil Bio's stock price?

The stock price of Instil Bio dropped following the announcement of the pause in clinical trials.

What does Holzer & Holzer, LLC investigate regarding Instil Bio?

Holzer & Holzer, LLC is investigating whether Instil Bio complied with federal securities laws related to the pause in clinical trials.

Who should contact Holzer & Holzer regarding Instil Bio?

Investors who purchased Instil Bio stock and incurred losses are encouraged to contact Holzer & Holzer.

What are the implications of the manufacturing issues reported by Instil Bio?

The manufacturing issues resulted in the inability to dose patients, raising concerns about the company's operational capabilities.